DAFNA Capital Management LLC Raises Stock Position in Bicara Therapeutics Inc. $BCAX

Key Points

• DAFNA Capital Management LLC has increased its holdings in Bicara Therapeutics Inc. by 100.9%, owning 212,001 shares worth $2.76 million as of the most recent SEC filing.
• Bicara Therapeutics reported earnings of (-$0.50) EPS for the last quarter, surpassing the consensus estimate of (-$0.54) by $0.04, with analysts predicting a total EPS of (-$2.59) for the current fiscal year.
• The stock has a current market capitalization of $651.45 million and a 52-week price range between $7.80 and $28.09, with an average analyst rating of Buy and a consensus price target of $32.25.

DAFNA Capital Management LLC increased its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 100.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,001 shares of the company's stock after buying an additional 106,501 shares during the period. DAFNA Capital Management LLC owned 0.39% of Bicara Therapeutics worth $2,762,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of BCAX. California State Teachers Retirement System bought a new position in Bicara Therapeutics in the fourth quarter worth about $25,000. CWM LLC bought a new position in Bicara Therapeutics in the first quarter worth about $29,000. BNP Paribas Financial Markets bought a new position in Bicara Therapeutics in the fourth quarter worth about $32,000. Legal & General Group Plc bought a new position in Bicara Therapeutics in the fourth quarter worth about $33,000. Finally, New York State Common Retirement Fund bought a new position in Bicara Therapeutics in the first quarter worth about $52,000.

Bicara Therapeutics Price Performance

Shares of BCAX traded down $0.04 on Tuesday, hitting $11.90. 376,731 shares of the stock traded hands, compared to its average volume of 266,722. The business has a 50 day simple moving average of $10.74 and a 200 day simple moving average of $11.86. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.04. As a group, equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target for the company in a research note on Friday, May 23rd. Wedbush reiterated an "outperform" rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Tuesday, August 12th. HC Wainwright lowered their target price on shares of Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a report on Friday, August 22nd. Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Piper Sandler started coverage on shares of Bicara Therapeutics in a report on Monday, August 18th. They set an "overweight" rating and a $36.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Bicara Therapeutics currently has a consensus rating of "Buy" and an average target price of $32.25.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.